These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 3034028)

  • 21. A double-blind study to compare the efficacy, tolerance and safety of two doses of the angiotensin converting enzyme inhibitor ramipril with placebo.
    Villamil AS; Cairns V; Witte PU; Bertolasi CA
    Am J Cardiol; 1987 Apr; 59(10):110D-114D. PubMed ID: 3034017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antihypertensive action and inhibition of tissue conversion enzyme by ramipril, perindopril and enalapril in the spontaneously hypertensive rat (SHRSP)].
    Unger T; Moursi MG; Lebrun C; Ganten D; Lang RE
    Arch Mal Coeur Vaiss; 1986 Jun; 79(6):971-4. PubMed ID: 3026275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loop diuretics combined with an ACE inhibitor for treatment of hypertension: a study with furosemide, piretanide, and ramipril in spontaneously hypertensive rats.
    Becker RH; Baldes L; Treudler M
    J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S35-9. PubMed ID: 2474099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ramipril: review of pharmacology.
    Becker RA; Schölkens B
    Am J Cardiol; 1987 Apr; 59(10):3D-11D. PubMed ID: 3034030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ramipril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders.
    Todd PA; Benfield P
    Drugs; 1990 Jan; 39(1):110-35. PubMed ID: 2138076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure.
    Kindler J; Schunkert H; Gassmann M; Lahn W; Irmisch R; Debusmann ER; Ocón-Pujadas J; Ritz E; Sieberth HG
    J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S55-8. PubMed ID: 2474105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic and pharmacodynamic properties of ramipril in patients with congestive heart failure (NYHA III-IV).
    Gerckens U; Grube E; Mengden T; Sigel H; Wagner WL; Lahn T; Irmisch R; Metzger H
    J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S49-51. PubMed ID: 2474102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An open multicenter study to assess the long-term efficacy, tolerance, and safety of the oral angiotensin converting enzyme inhibitor ramipril in patients with mild to moderate essential hypertension.
    Bauer B; Lorenz H; Zahlten R
    J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S70-4. PubMed ID: 2474109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First dose response and 24-hour antihypertensive efficacy of the new once-daily angiotensin converting enzyme inhibitor, ramipril.
    Heber ME; Brigden GS; Caruana MP; Lahiri A; Raftery EB
    Am J Cardiol; 1988 Aug; 62(4):239-45. PubMed ID: 2969671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Global and regional hemodynamic effects of ramipril in congestive heart failure.
    Crozier IG; Ikram H; Nicholls MG; Jans S
    J Cardiovasc Pharmacol; 1989 Nov; 14(5):688-93. PubMed ID: 2481181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of a new angiotensin-converting enzyme inhibitor, ramipril, vs. enalapril in essential hypertension: a multicenter trial.
    Mroczek WJ
    J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S147-9. PubMed ID: 1725028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic effects of ramipril treatment in hypertensive subjects with non-insulin-dependent diabetes mellitus.
    Janka HU; Nuber A; Mehnert H
    Arzneimittelforschung; 1990 Apr; 40(4):432-5. PubMed ID: 2141472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose-response relationship of ramipril in patients with mild-to-moderate hypertension.
    Schnaper HW
    J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S128-30. PubMed ID: 1725021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Ambulatory multicenter study of Triatec (ramipril). Observations concerning the lessons of the trial for the realization of future trials and for the management of hypertensive patients].
    Battaglia C; Gallet M; Carré A
    Rev Prat; 1990 Jun; 40(18 Suppl):45-7. PubMed ID: 2143598
    [No Abstract]   [Full Text] [Related]  

  • 35. The effect of ramipril on ambulatory blood pressure: a multicenter trial.
    Burris JF
    J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S131-3. PubMed ID: 1725022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preliminary experiences with HOE 498, a novel long-acting converting enzyme inhibitor, in hypertensive patients.
    de Leeuw PW; Lugtenburg PL; van Houten H; Looman JH; Birkenhäger WH
    J Cardiovasc Pharmacol; 1985; 7(6):1161-5. PubMed ID: 2418304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of renal function on the pharmacokinetics of ramipril (HOE 498).
    Debusmann ER; Pujadas JO; Lahn W; Irmisch R; Jané F; Kuan TS; Mora J; Walter U; Eckert HG; Hajdú P
    Am J Cardiol; 1987 Apr; 59(10):70D-78D. PubMed ID: 3034037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of the efficacy and safety of ramipril and digoxin added to maintenance diuretic treatment in patients with chronic heart failure.
    Kholeif MA; Pringle S; Kesson E; Murray G; Kennedy JA; Lorimer AR; Stock JK; Brown JJ
    J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S180-3. PubMed ID: 1725036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The French ambulatory multicenter trial of Triatec: conclusions of the trial].
    Le Menn G
    Rev Prat; 1990 Jun; 40(18 Suppl):48-50. PubMed ID: 2143599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Steady-state kinetics of ramipril in renal failure.
    Schunkert H; Kindler J; Gassmann M; Lahn W; Irmisch R; Debusmann ER; Ocón-Pujadas J; Sieberth HG
    J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S52-4. PubMed ID: 2474104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.